Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Employees: 47,000
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 245 | Existing positions closed: 163
27% more repeat investments, than reductions
Existing positions increased: 1,761 | Existing positions reduced: 1,390
18% more funds holding in top 10
Funds holding in top 10: 327 [Q4 2024] → 385 (+58) [Q1 2025]
12% more capital invested
Capital invested by funds: $604B [Q4 2024] → $677B (+$73B) [Q1 2025]
4.62% more ownership
Funds ownership: 82.1% [Q4 2024] → 86.72% (+4.62%) [Q1 2025]
0% less funds holding
Funds holding: 3,847 [Q4 2024] → 3,844 (-3) [Q1 2025]
7% less call options, than puts
Call options by funds: $9.22B | Put options by funds: $9.88B
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$700
12%
downside
Avg. target
$960
21%
upside
High target
$1,135
43%
upside
5 analyst ratings
4 positive
80%
0 neutral
0%
1 negative
20%
Guggenheim Seamus Fernandez | 19%upside $942 | Buy Maintained | 11 Jul 2025 |
Morgan Stanley Terence Flynn | 43%upside $1,135 | Overweight Maintained | 10 Jul 2025 |
UBS Trung Huynh | 32%upside $1,050 | Buy Maintained | 2 May 2025 |
HSBC Rajesh Kumar | 12%downside $700 | Reduce Downgraded | 28 Apr 2025 |
Cantor Fitzgerald Carter Gould | 23%upside $975 | Overweight Initiated | 22 Apr 2025 |
Financial journalist opinion
Based on 85 articles about LLY published over the past 30 days
Neutral
Schwab Network
10 hours ago
Orr: PLTR & NVDA are Overvalued, GOOGL & LLY Great Upcoming Picks
Steven E. Orr finds Palantir (PLTR) overvalued right now and is looking for it to pull back to $100/share. He feels the same about Nvidia (NVDA), citing market FOMO.
Positive
Zacks Investment Research
16 hours ago
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Positive
Seeking Alpha
1 day ago
Eli Lilly Comes Out As ADA Winner
Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming. Favorable commercial trends for tirzepatide and a robust pipeline—including orforglipron and retatrutide—support Lilly's continued market dominance for the next 5-7 years.
Positive
Schwab Network
1 day ago
The Big 3: AVGO, LLY, UBER
Joe Tigay joins today's Big 3 and turns to three stocks that he believes investors should keep on their radar as the market "broadens." He talks about the potential for Broadcom (AVGO) to continue its rally after its tremendous run higher, Eli Lilly's (LLY) role in the "vanity trade," and Uber Technologies (UBER) finding its "niche" as autonomous driving evolves.
Positive
Zacks Investment Research
1 day ago
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Neutral
Zacks Investment Research
1 day ago
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.
Positive
Zacks Investment Research
1 day ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Positive
Zacks Investment Research
2 days ago
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.
Positive
Proactive Investors
2 days ago
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable growth prospects and strong positioning in the obesity and diabetes markets. The bank made only minor adjustments to its revenue and earnings estimates through 2026, driven primarily by higher sales expectations for weight-loss drug Zepbound.
Positive
Benzinga
2 days ago
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.
Charts implemented using Lightweight Charts™